If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example

Published:2013-04 Issue:2 Volume:39 Page:189-198
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Vriens Birgit E.P.J.,Lobbezoo Dorien J.A.,de Hoon Joep P.J.,Veeck Jürgen,Voogd Adri C.,Tjan-Heijnen Vivianne C.G.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference54 articles.

1. Taxane containing regimens for metastatic breast cancer;Ghersi;Cochrane Database Syst Rev,2005

2. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer;Piccart-Gebhart;J Clin Oncol,2008

3. Taxanes for adjuvant treatment of early breast cancer;Ferguson;Cochrane Database Syst Rev,2007

4. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients;Bria;Cancer,2006

5. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials;De Laurentiis;J Clin Oncol,2008

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer;Nanomedicine;2021-02

2. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG);Breast Cancer Research and Treatment;2018-08-18

3. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study;The Breast;2017-08

4. Toxicity Evaluation and Anti-Tumor Study of Docetaxel Loaded mPEG-Polyester Micelles for Breast Cancer Therapy;Journal of Biomedical Nanotechnology;2017-04-01

5. A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium;Cancer Treatment and Research Communications;2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3